Drugs / LAVA-051
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04887259 | Jul 2021 → Sep 2023 | B-cell chronic lymphocytic leukemia, acute myeloid leukemia, plasma cell myeloma | Lava Therapeutics | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LAVA-051 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04887259 ↗ |
| Route | Intravenous | “administered via intravenous (IV) infusion” NCT04887259 ↗ |